Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

78.05 -1.51 (-1.90%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
70 71 Next >
AstraZeneca Puts Cambridge Expansion On Ice Adding Pressure On Starmer Ahead Of Trump Visit
AstraZeneca pauses its £200 million UK investment as rising costs, undervaluation, and unclear policies hinder pharma R&D and foreign capital inflows. 
Via Benzinga
Topics Government
The Weight of Progress: A New Era Dawns for Anti-Obesity Drugs, Reshaping Markets and Health
The global anti-obesity drug market is experiencing an unprecedented surge, driven by groundbreaking advancements in pharmacotherapy, particularly the advent of highly effective GLP-1 receptor... 
Via MarketMinute
Merck's Exit Highlights UK Risks Losing Pharma Investment Amid Rising Costs
Pharmaceutical companies are pulling investment from the UK as NHS drug spending falls and pricing disputes worsen. 
Via Benzinga
Retail Buzz Builds As AstraZeneca’s Tagrisso Combo Extends Lung Cancer Survival To Nearly 4 Years
Via Stocktwits
Fibrogen Gets Regulator’s Green Light To Sell China Unit To AstraZeneca
Via Stocktwits
China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order
Zai Labs and BeOne Medicines plummeted Wednesday on reports an executive order could reduce access to China-developed drugs. 
Via Investor's Business Daily
Topics Government
FDA Expands Approval For AstraZeneca's Drug For Pediatric Patients With Rare Type Of Cancer
The FDA approved AstraZeneca's Koselugo for children 1+ with NF1 and inoperable nerve tumors, expanding treatment options with an established safe dose. 
Via Benzinga
Trump's Biotech Playbook Ignites $350 Billion Investment Blitz
Trump's policies have sparked a $350B investment surge in US biotech, creating job & revenue opportunities. Investors can track with XBI or IBB ETFs and consider JNJ, NVS, LLY, AZN, BMY as potential... 
Via Benzinga
Topics ETFs Government
AstraZeneca Lung Cancer Combo Extends Patient Survival By Years In Key Study
AstraZeneca's Tagrisso with chemotherapy improved survival in advanced NSCLC, extending median overall survival by nearly 10 months over monotherapy. 
Via Benzinga
Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again
The company is working on a treatment for an autoimmune disease that affects the muscles. 
Via Investor's Business Daily
These 2 Healthcare Stocks More Than Doubled Recently and Could Soar Higher, According to Wall Street Analysts
Experts who follow these stocks think they can fly higher despite already gaining over 100% since the end of July. 
Via The Motley Fool
TAGRISSO® (osimertinib) plus chemotherapy demonstrated a median overall survival of nearly four years, the longest benefit ever reported in a global Phase III trial in EGFR-mutated advanced lung cancer
From AstraZeneca
Via Business Wire
AstraZeneca, Corning And More On CNBC's 'Final Trades'
On CNBC's “Halftime Report Final Trades,” Jim Lebenthal, partner at Cerity Partners, named AstraZeneca PLC (NASDAQ:AZN) as his 
Via Benzinga
Market Jitters: Wall Street Braces for Continued Volatility
The U.S. stock market is once again sending signals of caution, as major indices experienced a notable pullback from their recent record highs in early September 2025. This downturn, following a robust... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
AstraZeneca's Latest Drug Offers Hope For Millions Battling Hard-To-Control Blood Pressure
AstraZeneca's Baxdrostat met all endpoints in a Phase 3 trial, showing sustained blood pressure reductions in patients with resistant hypertension. 
Via Benzinga
Baxdrostat demonstrated statistically significant and clinically meaningful reduction in systolic blood pressure in patients with hard-to-control hypertension in the BaxHTN Phase III ​trial
From AstraZeneca
Via Business Wire
AstraZeneca's $80 Billion Ambition Just Got A Big Infusion With New Hypertension Results
AstraZeneca, on Saturday, unveiled promising results for a new hypertension treatment that aims to help the roughly 650,000 people. 
Via Investor's Business Daily
Looking Into AstraZeneca's Recent Short Interest
 
Via Benzinga
Get insights into the top gainers and losers of Tuesday's after-hours session.
As the regular session of the US market concludes on Tuesday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
Regeneron Advances In Rare Disease Race With Positive Autoimmune Muscle Disorder Trial Data
Regeneron's Phase 3 NIMBLE trial showed cemdisiran improved myasthenia gravis symptoms, with an FDA filing expected in early 2026. 
Via Benzinga
BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up
BeOne Medicines will sell global Imdelltra royalties to Royalty Pharma for up to $950 million while retaining rights to other oncology programs with Amgen. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
UK Drug Pricing Talks Collapse, Drugmakers Reject Offer Citing 'Uncompetitive' System
UK drug pricing talks collapsed after the government and pharma firms failed to agree on National Health Service rebates. 
Via Benzinga
J&J Commits $2 Billion To US Manufacturing Expansion Amid Threat Of Drug Tariffs
Johnson & Johnson (NYSE: JNJ) is set to invest $2 billion in its North Carolina facilities, expanding its U.S. manufacturing operations. This move comes in response to potential drug import tariffs... 
Via Benzinga
Topics Government World Trade
IonQ Expands Quantum IP Portfolio, Surpassing 1,000 Patents And Applications
IonQ, Inc. announces major progress in its IP strategy with new U.S. patents, reinforcing its leadership in quantum computing and potential for commercial advantage. 
Via Benzinga
Topics Intellectual Property
AstraZeneca Launches Home Delivery Service For Its Self-Administrable Flu Vaccine
Flumist can be self-administered by adults 18 to 49 years of age or administered by a parent or caregiver to individuals 2-17 years of age. 
Via Stocktwits
FLUMIST (Influenza, Vaccine Live, Intranasal), the nation’s only nasal spray flu vaccine, now available for home delivery
From AstraZeneca
Via Business Wire
White House Eyes Up to 250% Drug Tariffs In Bid To Reclaim US Pharma Supply Chain
White House trade adviser Peter Navarro discusses tariffs on pharma imports under a "Section 232" trade investigation. 
Via Benzinga
Topics World Trade
The Specter of Stagflation: Trump's Tariffs Cast a Long Shadow Over the U.S. Economy
Economists and investors are increasingly sounding the alarm over the growing risk of "stagflation," a perilous economic phenomenon characterized by high inflation coupled with stagnant economic... 
Via MarketMinute
Topics Economy Government Supply Chain
Sanofi, Eli Lilly, Novo Nordisk, AstraZeneca Face Renewed Claims Of Conspiring To Restrict 340B Discounts
A federal appeals court revived a lawsuit accusing Sanofi, Eli Lilly, Novo Nordisk, and AstraZeneca of conspiring to restrict 340B drug discounts for safety-net clinics, sending the case back to... 
Via Benzinga
Topics Lawsuit
< Previous 1 2 3 4 5 6 7 8 9
...
70 71 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.